The FDA announced that it approved the first generic version of Sabril tablets, Teva Pharmaceutical’s vigabatrin, for treating complex partial seizures, also called focal seizures, as an adjunctive therapy in patients 10 years and older who have responded inadequately to several alternative treatments. Labeling for vigabatrin tablets includes a boxed warning for permanent vision loss.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.